LT4936B - Tricikliai poli(adp-ribozės) polimerazių inhibitoriai - Google Patents

Tricikliai poli(adp-ribozės) polimerazių inhibitoriai Download PDF

Info

Publication number
LT4936B
LT4936B LT2001083A LT2001083A LT4936B LT 4936 B LT4936 B LT 4936B LT 2001083 A LT2001083 A LT 2001083A LT 2001083 A LT2001083 A LT 2001083A LT 4936 B LT4936 B LT 4936B
Authority
LT
Lithuania
Prior art keywords
mmol
compound
alkyl
pharmaceutically acceptable
tetrahydro
Prior art date
Application number
LT2001083A
Other languages
English (en)
Lithuanian (lt)
Other versions
LT2001083A (en
Inventor
Stephen Evan Webber
Stacie S. Canan-Koch
Jayashree Girish Tikhe
Lars Henrik Thoresen
Original Assignee
Agouron Pharmaceuticals,Inc.
Cancer Research Campaign Technology Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharmaceuticals,Inc., Cancer Research Campaign Technology Limited filed Critical Agouron Pharmaceuticals,Inc.
Publication of LT2001083A publication Critical patent/LT2001083A/xx
Publication of LT4936B publication Critical patent/LT4936B/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06Peri-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • A61K31/277Nitriles; Isonitriles having a ring, e.g. verapamil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
LT2001083A 1999-01-11 2001-08-10 Tricikliai poli(adp-ribozės) polimerazių inhibitoriai LT4936B (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11543199P 1999-01-11 1999-01-11

Publications (2)

Publication Number Publication Date
LT2001083A LT2001083A (en) 2002-03-25
LT4936B true LT4936B (lt) 2002-07-25

Family

ID=22361361

Family Applications (1)

Application Number Title Priority Date Filing Date
LT2001083A LT4936B (lt) 1999-01-11 2001-08-10 Tricikliai poli(adp-ribozės) polimerazių inhibitoriai

Country Status (39)

Country Link
US (4) US6495541B1 (enExample)
EP (1) EP1140936B1 (enExample)
JP (1) JP4093448B2 (enExample)
KR (1) KR100632079B1 (enExample)
CN (1) CN100418967C (enExample)
AP (1) AP1538A (enExample)
AT (1) ATE261963T1 (enExample)
AU (1) AU781711B2 (enExample)
BG (1) BG65210B1 (enExample)
BR (1) BRPI0008614B8 (enExample)
CA (1) CA2360003C (enExample)
CZ (1) CZ302941B6 (enExample)
DE (1) DE60009033T2 (enExample)
DK (1) DK1140936T3 (enExample)
EA (1) EA004989B1 (enExample)
EE (1) EE05006B1 (enExample)
ES (1) ES2218110T3 (enExample)
GE (1) GEP20033055B (enExample)
HR (1) HRP20010573B1 (enExample)
HU (1) HU229875B1 (enExample)
ID (1) ID30138A (enExample)
IL (2) IL144112A0 (enExample)
IS (1) IS5995A (enExample)
LT (1) LT4936B (enExample)
LV (1) LV12770B (enExample)
MX (1) MXPA01007001A (enExample)
NO (1) NO320343B1 (enExample)
NZ (1) NZ512731A (enExample)
OA (2) OA11749A (enExample)
PL (1) PL210415B1 (enExample)
PT (1) PT1140936E (enExample)
RO (1) RO121778B1 (enExample)
RS (1) RS50031B (enExample)
SI (1) SI20691B (enExample)
SK (1) SK287338B6 (enExample)
TR (1) TR200102005T2 (enExample)
UA (1) UA75034C2 (enExample)
WO (1) WO2000042040A1 (enExample)
ZA (1) ZA200105399B (enExample)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291425B1 (en) 1999-09-01 2001-09-18 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
IL143349A0 (en) * 1999-09-28 2002-04-21 Basf Ag Azepinoindole derivatives, the production and use thereof
US6589725B1 (en) 1999-10-25 2003-07-08 Rigel Pharmaceuticals, Inc. Tankyrase H, compositions involved in the cell cycle and methods of use
US6531464B1 (en) 1999-12-07 2003-03-11 Inotek Pharmaceutical Corporation Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives
US6476048B1 (en) 1999-12-07 2002-11-05 Inotek Pharamaceuticals Corporation Substituted phenanthridinones and methods of use thereof
PT1268407E (pt) * 2000-03-20 2004-11-30 N Gene Res Lab Inc Derivados de amidoxima de acido propenocarboxilico, um processo para a sua preparacao e composicoes farmaceuticas contendo os mesmos
US6534651B2 (en) 2000-04-06 2003-03-18 Inotek Pharmaceuticals Corp. 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof
EP1339402B1 (en) 2000-12-01 2010-08-25 Eisai Inc. Azaphenanthridone derivatives and their use as parp inhibitors
US6664269B2 (en) 2001-05-08 2003-12-16 Maybridge Plc Isoquinolinone derivatives
CN1568187A (zh) 2001-08-15 2005-01-19 Icos股份有限公司 2h-2,3-二氮杂萘-1-酮和其使用方法
US6956035B2 (en) 2001-08-31 2005-10-18 Inotek Pharmaceuticals Corporation Isoquinoline derivatives and methods of use thereof
US20030096833A1 (en) 2001-08-31 2003-05-22 Jagtap Prakash G. Substituted ideno[1,2-c]isoquinoline derivatives and methods of use thereof
AU2002358650A1 (en) * 2001-12-14 2003-06-30 Altana Pharma Ag Known and novel 4,5-dihydro-imidazo(4,5,1-ij)quinolin-6-ones useful as poly(adp-ribose)polymerase inhibitors
DE60335359D1 (de) 2002-04-30 2011-01-27 Kudos Pharm Ltd Phthalazinonderivate
KR100697746B1 (ko) 2003-01-09 2007-03-22 화이자 인코포레이티드 키나제 저해제로서의 디아제피노인돌 유도체
US7217709B2 (en) 2003-02-28 2007-05-15 Inotek Pharmaceuticals Corporation Tetracyclic benzamide derivatives and methods of use thereof
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
WO2004087713A1 (en) * 2003-03-31 2004-10-14 Pfizer Inc. Salts of tricyclic inhibitors of poly(adp-ribose) polymerases
JP4824566B2 (ja) * 2003-05-28 2011-11-30 エーザイ インコーポレーテッド Parpを阻害するための化合物、方法、および医薬組成物
DK1660095T3 (da) * 2003-07-25 2010-05-25 Cancer Rec Tech Ltd Tricykliske PARP-inhibitorer
GB0317466D0 (en) 2003-07-25 2003-08-27 Univ Sheffield Use
PT2305221E (pt) 2003-12-01 2015-09-03 Cancer Res Inst Inibidores de reparação de danos no adn para tratamento de cancro
EP2033645A1 (en) 2004-02-26 2009-03-11 Inotek Pharmaceuticals Corporation Isoquinoline derivatives and methods of use thereof
GB0419072D0 (en) 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
RU2344138C2 (ru) * 2004-09-22 2009-01-20 Пфайзер Инк. Способ получения ингибиторов поли(адф-рибоза)полимераз
ATE551345T1 (de) * 2004-09-22 2012-04-15 Pfizer Polymorphe formen des phosphatsalzes von 8-fluor- 2-ä4-ä(methylamino)methylüphenylü-1,3,4,5- tetrahydro-6h-azepinoä5,4,3-cdüindol-6-on
MX2007003314A (es) * 2004-09-22 2007-08-06 Pfizer Combinaciones terapeuticas que comprenden inhibidor de poli(adp-ribosa)polimerasas.
CN101133061B (zh) * 2004-09-22 2011-09-07 辉瑞有限公司 8-氟-2-{4-[(甲基氨基)甲基]苯基}-1,3,4,5-四氢-6H-氮杂卓并[5,4,3-cd]吲哚-6-酮的磷酸盐的多晶型物和非晶物
WO2006078711A2 (en) 2005-01-19 2006-07-27 Mgi Gp, Inc. Diazabenzo[de]anthracen-3-one compounds and methods for inhibiting parp
EP1855676A4 (en) 2005-02-25 2008-05-21 Inotek Pharmaceuticals Corp TETRAZYCLIC AMINO AND CARBOXAMIDE COMPOUNDS AND METHOD FOR THEIR USE
US7297700B2 (en) 2005-03-24 2007-11-20 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
DE102005022111A1 (de) * 2005-05-12 2006-11-16 Siemens Ag Verfahren zum Datenaustausch
US20090226412A1 (en) 2005-06-24 2009-09-10 Ono Pharmaceutical Co., Ltd., Agent for reduction of bleeding in cerebrovascular disorder
BRPI0613460A2 (pt) 2005-07-14 2011-01-11 Irm Llc compostos e composições como inibidores de proteìna cinase
KR20130028149A (ko) 2005-07-18 2013-03-18 바이파 사이언스 인코포레이티드 암의 치료
KR20080039508A (ko) 2005-08-24 2008-05-07 이노텍 파마슈티컬스 코포레이션 인데노이소퀴놀리논 유사체 및 이의 사용 방법
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
DK2338487T3 (da) * 2006-01-17 2013-12-09 Abbvie Bahamas Ltd Kombinationsterapi med PARP-inhibitorer
TWI464148B (zh) 2006-03-16 2014-12-11 Evotec Us Inc 作為p2x7調節劑之雙環雜芳基化合物與其用途
US20080262062A1 (en) * 2006-11-20 2008-10-23 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
JP2010502731A (ja) 2006-09-05 2010-01-28 バイパー サイエンシズ,インコーポレイティド Parp阻害剤による脂肪酸合成の阻害、及びその治療方法
AU2007292387A1 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Treatment of cancer
RU2009135818A (ru) 2007-02-28 2011-04-10 Инотек Фармасьютикалз Корпорейшн (Us) Инденоизохинолиноновые аналоги и способы их применения
WO2008154129A1 (en) * 2007-06-08 2008-12-18 Bausch & Lomb Incorporated Pharmaceutical compositions and method for treating, reducing, ameliorating, alleviating, or preventing dry eye
EP2188278A1 (en) 2007-09-14 2010-05-26 AstraZeneca AB Phthalazinone derivatives
PL2209375T3 (pl) 2007-10-03 2014-12-31 Eisai Inc Związki, kompozycje i metody stosowania inhibitorów PARP
US7732491B2 (en) 2007-11-12 2010-06-08 Bipar Sciences, Inc. Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents
AR070221A1 (es) 2008-01-23 2010-03-25 Astrazeneca Ab Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
GB0804755D0 (en) 2008-03-14 2008-04-16 Angeletti P Ist Richerche Bio Therapeutic compounds
CN102238945B (zh) 2008-10-07 2014-10-29 阿斯利康(英国)有限公司 药物制剂514
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
KR100986820B1 (ko) * 2010-01-27 2010-10-12 (주)에코베이스 막힘방지형 고효율 산기장치 및 이를 이용한 수질정화장치
JP5745283B2 (ja) 2010-02-12 2015-07-08 ファイザー・インク 8−フルオロ−2−{4−[(メチルアミノ)メチル]フェニル}−1,3,4,5−テトラヒドロ−6H−アゼピノ[5,4,3−cd]インドール−6−オンの塩および多形体
US8999985B2 (en) 2010-12-02 2015-04-07 Shanghai De Novo Pharmatech Co Ltd. Substituted phthalazin-1(2H)-ones, preparation processes and medical uses thereof
AU2011384859B2 (en) 2011-12-31 2016-03-17 Beigene, Ltd. Fused tetra or penta-cyclic pyridophthalazinones as PARP inhibitors
HRP20171883T1 (hr) 2011-12-31 2018-01-12 BeiGene, Ltd., Mourant Ozannes, Corporate Services (Cayman) Limited Kondenzirani tetra ili penta-ciklički dihidrodiazepinokarbazoloni kao parp inhibitori
JP6223995B2 (ja) 2012-11-08 2017-11-01 日本化薬株式会社 カンプトテシン類と抗癌効果増強剤の結合した高分子化合物及びその用途
EP3424909A1 (en) 2014-01-05 2019-01-09 Washington University A poly (adp-ribose) polymerase-1 (parp-1) inhibitor and uses therefor
CN103772395B (zh) * 2014-01-23 2016-05-11 中国药科大学 一类具有parp抑制活性的化合物、其制备方法及用途
CA2950780C (en) 2014-06-17 2023-05-16 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of chk1 and atr inhibitors
LT3182975T (lt) 2014-08-22 2025-11-25 Tabletės su didele rukaparibo doze
CN105607772B (zh) * 2014-11-13 2020-11-03 现代自动车株式会社 触摸输入装置以及包括该装置的车辆
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
JP6871169B2 (ja) 2015-03-02 2021-05-12 シナイ ヘルス システム 相同組換え因子
CA2993270C (en) 2015-07-23 2019-07-16 Institut Curie Use of a combination of dbait molecule and parp inhibitors to treat cancer
IL296835A (en) 2015-08-25 2022-11-01 Beigene Ltd Process for preparing parp inhibitor, crystalline forms, and uses thereof
WO2017059357A1 (en) 2015-09-30 2017-04-06 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of dna damaging agents and atr inhibitors
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
CN107286166B (zh) * 2016-04-11 2020-03-31 上海勋和医药科技有限公司 取代1,3,4,5-四氢-6h-吡咯并[4,3,2-ef][2]苯并氮杂-6-酮衍生物
WO2018022851A1 (en) 2016-07-28 2018-02-01 Mitobridge, Inc. Methods of treating acute kidney injury
CN110087730B (zh) 2016-09-27 2023-03-28 百济神州(苏州)生物科技有限公司 使用包含parp抑制剂的组合产品治疗癌症
JP6541635B2 (ja) * 2016-10-28 2019-07-10 ベイジーン リミテッド Parp阻害剤としての縮合四環式または縮合五環式ジヒドロジアゼピノカルバゾロン
MA46779A (fr) 2016-11-02 2019-09-11 Health Research Inc Traitement combiné avec des conjugués anticorps-médicament et des inhibiteurs de parp
CN106854172B (zh) * 2016-12-11 2019-04-19 山东轩德医药科技有限公司 一种6-氟-1h-吲哚-4-甲酸甲酯的制备方法
WO2018122168A1 (en) 2016-12-29 2018-07-05 Bayer Pharma Aktiengesellschaft Combinations of bub1 kinase and parp inhibitors
HRP20241280T1 (hr) 2017-01-24 2024-12-06 Assia Chemical Industries Ltd. Kruti oblici rukapariba i soli rukapariba
CN106748958B (zh) * 2017-01-25 2018-12-18 伦俊杰 一种Rucaparib中间体的制备方法
CN110392687B (zh) 2017-02-28 2022-08-02 百济神州(苏州)生物科技有限公司 稠合的四环或五环二氢二氮杂䓬并咔唑酮的盐的结晶形式及其用途
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
WO2018218025A1 (en) * 2017-05-24 2018-11-29 The Trustees Of The University Of Pennsylvania Radiolabeled and fluorescent parp inhibitors for imaging and radiotherapy
IT201700085789A1 (it) 2017-07-26 2019-01-26 Olon Spa Metodo per la preparazione di rucaparib ad elevata purezza
WO2019023621A1 (en) 2017-07-28 2019-01-31 Yale University ANTICANCER DRUGS AND METHODS OF MAKING AND USING THEM
CN109651376B (zh) * 2017-10-12 2022-06-03 江苏创诺制药有限公司 一种氮杂卓并[5,4,3-cd]吲哚-6-酮化合物的合成方法
CN109651377B (zh) * 2017-10-12 2020-10-20 成都海创药业有限公司 一种治疗癌症的化合物及其用途
CA3080657A1 (en) 2017-11-03 2019-05-09 Sandoz Ag Crystalline salt of a tricyclic poly(adp-ribose) polymerase inhibitor
WO2019115000A1 (en) 2017-12-15 2019-06-20 Advitech Advisory And Technologies Sa Process for the preparation of rucaparib and novel synthesis intermediates
WO2019130229A1 (en) 2017-12-28 2019-07-04 Mylan Laboratories Ltd Methods and intermediates for preparing rucaparib
PE20211305A1 (es) * 2018-01-05 2021-07-20 Cybrexa 1 Inc Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas
US10442813B2 (en) 2018-01-30 2019-10-15 RK Pharma Solutions LLC Polymorphs of rucaparib camsylate and methods of making same
CN110229162B (zh) * 2018-03-05 2020-08-11 新发药业有限公司 一种瑞卡帕布的简便制备方法
CN111819282A (zh) 2018-03-13 2020-10-23 欧恩科斯欧公司 对抗癌症治疗中获得性耐药性的Dbait分子
CN110272419A (zh) * 2018-03-14 2019-09-24 上海艾力斯医药科技有限公司 二氢吡啶并酞嗪酮衍生物、其制备方法及应用
WO2019207596A1 (en) 2018-04-25 2019-10-31 Mylan Laboratories Limited Novel crystalline forms of rucaparib (s)-camsylate salt and rucaparib free base
CN108743557A (zh) * 2018-06-27 2018-11-06 李莉 一种磷酸瑞卡帕布软胶囊及其制备方法
CN108976236B (zh) * 2018-08-16 2020-11-10 湖南华腾制药有限公司 一种氘代parp抑制剂、其盐、其制备方法及用途
CN113454080B (zh) 2018-10-30 2025-10-28 修复治疗公司 化合物、药物组合物和制备化合物的方法以及其使用方法
CN111217818A (zh) 2018-11-27 2020-06-02 台耀化学股份有限公司 芦卡帕尼樟脑磺酸盐的结晶、及制备三环化合物、芦卡帕尼及其樟脑磺酸盐结晶的方法
BR112021015149A2 (pt) * 2019-02-02 2021-09-28 Chia Tai Tianqing Pharmaceutical Group Co., Ltd Análogo de indolo heptamil oxima como inibidor de parp
CN110256468B (zh) * 2019-05-14 2020-09-01 山东省分析测试中心 双吲哚生物碱化合物或其药学上可接受的盐及其制备方法和应用
JP7370032B2 (ja) 2019-05-14 2023-10-27 スーヂョウ フォー ヘルス ファーマスーティカルズ カンパニー リミテッド Parr阻害剤としてのキナゾリン―2.4―ジオン誘導体
JP7675060B2 (ja) 2019-07-10 2025-05-12 サイブレクサ 3,インコーポレイテッド 治療薬としての微小管標的化剤のペプチドコンジュゲート
CR20220058A (es) 2019-07-10 2022-07-19 Cybrexa 2 Inc Conjugados peptídicos de citotoxinas como terapéuticos
CN114072410B (zh) * 2019-08-01 2023-08-01 正大天晴药业集团股份有限公司 作为parp抑制剂吲哚并七元酰肟化合物
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021156140A1 (en) 2020-02-03 2021-08-12 Sandoz Ag Polymorph of rucaparib mesylate
CN113288892B (zh) * 2020-02-24 2024-04-26 甫康(上海)健康科技有限责任公司 聚adp核糖聚合酶抑制剂在抗冠状病毒中的应用
CA3176206A1 (en) 2020-04-28 2021-11-04 Debnath Bhuniya Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors
CN111646990B (zh) * 2020-05-22 2023-01-10 同济大学 一种3,4-桥环吲哚类化合物的制备方法及Rucaparib的合成方法
CN111662299B (zh) * 2020-07-10 2022-07-26 中山大学 一种取代吲哚并氮杂酮类化合物及其制备方法和应用
WO2022015557A1 (en) 2020-07-14 2022-01-20 Assia Chemical Industries Ltd Solid state forms of rucaparib salts
WO2022022664A1 (zh) * 2020-07-31 2022-02-03 正大天晴药业集团股份有限公司 用作parp抑制剂的吲哚并七元酰肟类似物的结晶及其制备方法
CN111961047A (zh) * 2020-08-19 2020-11-20 南通大学 一种6-乙氧基-3,4-二氢-2,7-萘啶-1(2h)-酮及其合成方法
WO2022090938A1 (en) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Phthalazinone derivatives useful as parp inhibitors
MX2023008146A (es) 2021-01-08 2023-07-24 Cybrexa 2 Inc Proceso para preparar un resto enlazador de conjugados.
WO2022155172A1 (en) 2021-01-13 2022-07-21 Cybrexa 3, Inc. Peptide conjugates of therapeutics
MX2023011793A (es) 2021-04-08 2023-10-12 Rhizen Pharmaceuticals Ag Inhibidores de poli(adenosin difosfato-ribosa) polimerasa.
BR112023023813A2 (pt) * 2021-05-18 2024-02-06 Onconic Therapeutics Inc Forma cristalina de composto derivado tricíclico, método para preparar a mesma, e composição farmacêutica que compreende a mesma
EP4463232A1 (en) 2022-01-11 2024-11-20 Assia Chemical Industries Ltd. Solid state forms of rucaparib tosylate
WO2023201338A1 (en) 2022-04-15 2023-10-19 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and a parp inhibitor
CN119451954A (zh) 2022-06-01 2025-02-14 伊迪亚生物科学有限公司 作为DNA聚合酶θ抑制剂的噻二唑基衍生物及其用途
WO2024261711A1 (en) * 2023-06-21 2024-12-26 Valo Health, Inc. Homophthalazinone indole parp inhibitors and methods of use
WO2024261243A1 (en) 2023-06-21 2024-12-26 Hemispherian As Combination comprising a deoxycytidine derivative and a parp inhibitor for use in a method of treating hr proficient cancer
US12383633B1 (en) * 2024-10-01 2025-08-12 Zymeron Corporation Injectable formulations of PARP inhibitors and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5589483A (en) 1994-12-21 1996-12-31 Geron Corporation Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence
US5756510A (en) 1994-03-09 1998-05-26 Newcastle University Ventures Limited Benzamide analogs useful as PARP (ADP-ribosyltransferase, ADPRT) DNA repair enzyme inhibitors

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3642820A (en) 1969-11-03 1972-02-15 Upjohn Co 4 5-dihydropyrrolo(3 2 1-jk)(1 4)bezodiazepines
US3883590A (en) 1971-06-01 1975-05-13 Universal Oil Prod Co Preparation of n-alkylarylcarboxamides
DE2322434A1 (de) 1973-05-04 1974-11-21 Bayer Ag 2-trifluormethylimino-1,3-dithioloeckige klammer auf 4,5-b eckige klammer zu -chinoxaline, verfahren zu ihrer herstellung, sowie ihre verwendung als insektizide, akarizide und fungizide
US4033960A (en) 1973-07-31 1977-07-05 Bayer Aktiengesellschaft 2-Mercaptoquinoxaline-di-N-oxide products and a method for their preparation
US3900477A (en) * 1973-11-06 1975-08-19 Ayerst Mckenna & Harrison 5-amino-and 5-hydrazinodihydropyrroloisoquinoline derivatives
US3978066A (en) 1973-11-06 1976-08-31 Ayerst, Mckenna And Harrison Ltd. Certain 4,6-dihydropyrrolotriazoline-quinoline derivatives
US3950343A (en) 1973-11-06 1976-04-13 Ayerst, Mckenna And Harrison Ltd. Pyrroloisoquinoline derivatives
US3959343A (en) * 1974-10-25 1976-05-25 Wako Pure Chemical Industries, Ltd. Process for producing hydrazonitriles
DE2913728A1 (de) 1979-04-05 1980-10-16 Bayer Ag 2-sulfonyl-chinoxaline, verfahren zu ihrer herstellung sowie ihre verwendung als mikrobizide
DE3103137A1 (de) 1981-01-30 1982-08-26 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung aliphatischer cyclischer kohlensaeureester
JPS57144286A (en) 1981-03-02 1982-09-06 Takeda Chem Ind Ltd Azepinoindole derivative and its preparation
US5215738A (en) 1985-05-03 1993-06-01 Sri International Benzamide and nicotinamide radiosensitizers
US4910193A (en) 1985-12-16 1990-03-20 Sandoz Ltd. Treatment of gastrointestinal disorders
JPS6434988A (en) * 1987-07-30 1989-02-06 Kissei Pharmaceutical Azepinoindole derivative
DE4125292A1 (de) * 1991-07-31 1993-02-04 Kali Chemie Pharma Gmbh 6-oxo-azepinoindol-verbindungen sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
GB9117987D0 (en) 1991-08-20 1991-10-09 Ici Plc Heterocyclic compounds
US5342946A (en) 1992-12-02 1994-08-30 Guilford Pharmaceuticals Inc. Phosphonoalkylquinolin-2-ones as novel antagonists of non-NMDA ionotropic excitatory amino acid receptors
CN1114834A (zh) 1993-09-28 1996-01-10 大塚制药株式会社 抗糖尿病剂
US5587384A (en) 1994-02-04 1996-12-24 The Johns Hopkins University Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity
US5561161A (en) 1994-03-25 1996-10-01 Oxigene, Inc. Methods of administering and pharmaceutical formulations containing n-substituted benzamides and/or acid addition salts thereof
ES2105959B1 (es) 1995-01-17 1998-07-01 Zeneca Pharma Sa Derivados de 1,4-dioxido de quinoxalina, procedimiento de preparacion y de utilizacion.
US5659082A (en) 1995-04-03 1997-08-19 Centaur Pharmaceuticals, Inc. Nitro- and aminobenzamide compounds for neurodegenerative disorders
US5756548A (en) 1995-04-03 1998-05-26 Centaur Pharmaceuticals, Inc. Acetamidobenzamide compounds for neurodegenerative disorders
PT841924E (pt) * 1995-08-02 2003-02-28 Univ Newcastle Ventures Ltd Compostos de benzimidazolo
HUT76302A (en) 1995-11-30 1997-07-28 Chinoin Gyogyszer Es Vegyeszet Quinoxaline derivatives, pharmaceutical compositions containing them and process for producing them
US6028111A (en) 1996-03-08 2000-02-22 Oxigene, Inc. Compositions and use of benzamides and nicotinamides as anti-inflammatory agents
GB9702701D0 (en) 1997-02-01 1997-04-02 Univ Newcastle Ventures Ltd Quinazolinone compounds
WO1998051307A1 (en) 1997-05-13 1998-11-19 Octamer, Inc. METHODS FOR TREATING INFLAMMATION, INFLAMMATORY DISEASES, ARTHRITIS AND STROKE USING pADPRT INHIBITORS
US20020028813A1 (en) 1997-09-03 2002-03-07 Paul F. Jackson Thioalkyl compounds, methods, and compositions for inhibiting parp activity
AU9298198A (en) 1997-09-03 1999-03-22 Guilford Pharmaceuticals Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
US6514983B1 (en) 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
US6635642B1 (en) 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US20020022636A1 (en) 1997-09-03 2002-02-21 Jia-He Li Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
US6197785B1 (en) 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
AU9298098A (en) 1997-09-03 1999-03-22 Guilford Pharmaceuticals Inc. Amino-substituted compounds, methods, and compositions for inhibiting parp activity
EP1077944A1 (en) 1998-05-15 2001-02-28 Guilford Pharmaceuticals Inc. Carboxamide compounds, compositions, and methods for inhibiting parp activity
CA2332239A1 (en) * 1998-05-15 1999-11-25 Guilford Pharmaceuticals Inc. Fused tricyclic compounds which inhibit parp activity
IL143349A0 (en) 1999-09-28 2002-04-21 Basf Ag Azepinoindole derivatives, the production and use thereof
DE19946289A1 (de) 1999-09-28 2001-03-29 Basf Ag Benzodiazepin-Derivate, deren Herstellung und Anwendung

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756510A (en) 1994-03-09 1998-05-26 Newcastle University Ventures Limited Benzamide analogs useful as PARP (ADP-ribosyltransferase, ADPRT) DNA repair enzyme inhibitors
US5589483A (en) 1994-12-21 1996-12-31 Geron Corporation Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BANASIK ET AL.: "Specific Inhibitorsss of Poly(ADP-Ribose) Synthetase and Mono(ADP-Ribosil)transferase", J. BIOL. CHEM., 1992, pages 1569 - 1575
ENDRES ET AL.: "Ischemic Brain Injury is Mediated by the Activation of Poly(ADP-Ribose)Polymerase", J. CEREBRAL BLOOD FLOW METAB., 1997, pages 1143 - 1151
SZABO ET AL.: "Protection Against Peroyyynitrite-induced Fibroblast Injury and Arthritis Development by inhibition of poly(ADP-ribose) Synthetase", PROC. NATI. ACAD. SCI. USA, 1998, pages 3867 - 3872

Also Published As

Publication number Publication date
LT2001083A (en) 2002-03-25
ID30138A (id) 2001-11-08
HU229875B1 (en) 2014-11-28
PL357049A1 (en) 2004-07-12
CZ20012443A3 (cs) 2002-02-13
IS5995A (is) 2001-07-10
BR0008614B1 (pt) 2014-11-25
CA2360003C (en) 2012-07-10
HK1040992A1 (en) 2002-06-28
CA2360003A1 (en) 2000-07-20
JP2002534523A (ja) 2002-10-15
SI20691A (sl) 2002-04-30
BG65210B1 (bg) 2007-07-31
JP4093448B2 (ja) 2008-06-04
CN100418967C (zh) 2008-09-17
OA12185A (en) 2006-05-09
EA004989B1 (ru) 2004-10-28
TR200102005T2 (tr) 2001-12-21
BG105811A (en) 2002-05-31
SK9662001A3 (en) 2002-04-04
YU49001A (sh) 2005-11-28
LV12770B (lv) 2002-05-20
IL144112A0 (en) 2002-05-23
AU2408800A (en) 2000-08-01
NZ512731A (en) 2004-01-30
OA11749A (en) 2005-07-19
AP1538A (en) 2006-01-10
EE200100364A (et) 2002-10-15
US6495541B1 (en) 2002-12-17
PL210415B1 (pl) 2012-01-31
PT1140936E (pt) 2004-06-30
US7429578B2 (en) 2008-09-30
HRP20010573B1 (en) 2006-04-30
EP1140936A1 (en) 2001-10-10
RS50031B (sr) 2008-11-28
US20050085460A1 (en) 2005-04-21
RO121778B1 (ro) 2008-04-30
US20060009517A1 (en) 2006-01-12
BR0008614A (pt) 2001-10-16
CN1342161A (zh) 2002-03-27
DE60009033T2 (de) 2004-08-05
NO320343B1 (no) 2005-11-28
NO20013313D0 (no) 2001-07-04
DE60009033D1 (de) 2004-04-22
SI20691B (sl) 2008-10-31
AP2001002211A0 (en) 2001-09-30
ATE261963T1 (de) 2004-04-15
AU781711B2 (en) 2005-06-09
MXPA01007001A (es) 2002-07-30
LV12770A (en) 2001-12-20
EE05006B1 (et) 2008-04-15
US6977298B2 (en) 2005-12-20
HRP20010573A2 (en) 2005-02-28
WO2000042040A1 (en) 2000-07-20
UA75034C2 (en) 2006-03-15
KR100632079B1 (ko) 2006-10-04
EP1140936B1 (en) 2004-03-17
EA200100764A1 (ru) 2002-06-27
GEP20033055B (en) 2003-08-25
KR20020008112A (ko) 2002-01-29
CZ302941B6 (cs) 2012-01-25
SK287338B6 (sk) 2010-07-07
US20030078254A1 (en) 2003-04-24
BRPI0008614B8 (pt) 2021-05-25
NO20013313L (no) 2001-09-10
ZA200105399B (en) 2002-07-01
ES2218110T3 (es) 2004-11-16
HUP0105414A2 (hu) 2002-05-29
HUP0105414A3 (en) 2003-04-28
IL144112A (en) 2006-07-05
DK1140936T3 (da) 2004-06-21

Similar Documents

Publication Publication Date Title
LT4936B (lt) Tricikliai poli(adp-ribozės) polimerazių inhibitoriai
EP1208104B1 (en) Tricyclic inhibitors of poly(adp-ribose) polymerases
TWI487707B (zh) 3,4-二氫吡咯并[1,2-a]吡-2,8(1h)-二碳醯胺衍生物及其製備與治療用途
HK1040992B (en) Tricyclic inhibitors of poly(adp-ribose) polymerases

Legal Events

Date Code Title Description
MM9A Lapsed patents

Effective date: 20120110